These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35726542)

  • 1. OMICRON: Virology, immunopathogenesis, and laboratory diagnosis.
    Bazargan M; Elahi R; Esmaeilzadeh A
    J Gene Med; 2022 Jul; 24(7):e3435. PubMed ID: 35726542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L
    J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask.
    Shin DH; Smith DM; Choi JY
    Yonsei Med J; 2022 Nov; 63(11):977-983. PubMed ID: 36303305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron variant evolution on vaccines and monoclonal antibodies.
    Sabbatucci M; Vitiello A; Clemente S; Zovi A; Boccellino M; Ferrara F; Cimmino C; Langella R; Ponzo A; Stefanelli P; Rezza G
    Inflammopharmacology; 2023 Aug; 31(4):1779-1788. PubMed ID: 37204696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
    Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
    Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.
    Alkhatib M; Salpini R; Carioti L; Ambrosio FA; D'Anna S; Duca L; Costa G; Bellocchi MC; Piermatteo L; Artese A; Santoro MM; Alcaro S; Svicher V; Ceccherini-Silberstein F
    Microbiol Spectr; 2022 Apr; 10(2):e0273221. PubMed ID: 35352942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Feikin DR; Higdon MM; Andrews N; Collie S; Deloria Knoll M; Kwong JC; Link-Gelles R; Pilishvili T; Patel MK
    Vaccine; 2023 Mar; 41(14):2329-2338. PubMed ID: 36797097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants.
    Fryer HA; Geers D; Gommers L; Zaeck LM; Tan NH; Jones-Freeman B; Goorhuis A; Postma DF; Visser LG; Hogarth PM; Koopmans MPG; GeurtsvanKessel CH; O'Hehir RE; van der Kuy PHM; de Vries RD; van Zelm MC
    J Infect; 2024 Oct; 89(4):106246. PubMed ID: 39127451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review.
    Chenchula S; Amerneni KC; Ghanta MK; Padmavathi R; Chandra MB; Adusumilli MB; Chavan M; Mudda S; Gupta R; Lakhawat B
    Virology; 2023 Jul; 584():38-43. PubMed ID: 37229914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters.
    Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani HH; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
    J Virol; 2023 Sep; 97(9):e0062823. PubMed ID: 37676002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron subvariants progressively adapt to human cells with altered host cell entry.
    Sakurai Y; Okada S; Ozeki T; Yoshikawa R; Kinoshita T; Yasuda J
    mSphere; 2024 Sep; 9(9):e0033824. PubMed ID: 39191389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms responsible for SARS-CoV-2 antibody waning and vaccine escape in Omicron sublineages BA.4 and BA.5.
    Hewins B; Richardson C; Rubino S; Kelvin A; Toloue Ostadgavahi A; Kelvin DJ
    J Infect Dev Ctries; 2022 Jul; 16(7):1122-1125. PubMed ID: 35905015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.